TY - JOUR
T1 - Narrowband UV-B (TL-01) phototherapy vs oral 8-methoxypsoralen psoralen - UV-A for the treatment of chronic plaque psoriasis
AU - Markham, Trevor
AU - Rogers, S.
AU - Collins, P.
PY - 2003/3/1
Y1 - 2003/3/1
N2 - Objective: To compare the efficacy of narrowband UV-B (TL-01) phototherapy with oral 8-methoxypsoralen photochemotherapy (8-MOP psoralen-UV-A [PUVA]) in patients with chronic plaque psoriasis (CPP). Design: Open, randomized, controlled study. Setting: Phototherapy unit in a dermatology hospital. Patients: Fifty-four patients with CCP. Interventions: Patients received whole-body threshold erythemogenic dose of either 3-times weekly TL-01 or twice-weekly oral 8-MOP PUVA, based on minimal erythema or phototoxic doses. Patients were treated until completely clear. Outcome Measures: Number of treatments to clear, number of days in treatment, number of days in remission, and adverse effects of both therapies were assessed. Results: Forty-five patients completed the study. Those in the PUVA group required significantly fewer treatments to clear (P = .03). There was no significant difference in the number of days to clear or number of days in remission. A similar percentage of patients in the TL-01 and PUVA groups developed minimal perceptible erythema, showing that the regimens were equally erythemogenic. Asymptomatic, well-defined erythema occurred only in the PUVA group. Pruritus and polymorphic light eruption occurred equally in both groups, but only patients in the PUVA group developed nausea. Conclusion: Narrowband UV-B phototherapy, used 3 times weekly, is as effective for the treatment of CPP as oral 8-MOP PUVA used twice weekly.
AB - Objective: To compare the efficacy of narrowband UV-B (TL-01) phototherapy with oral 8-methoxypsoralen photochemotherapy (8-MOP psoralen-UV-A [PUVA]) in patients with chronic plaque psoriasis (CPP). Design: Open, randomized, controlled study. Setting: Phototherapy unit in a dermatology hospital. Patients: Fifty-four patients with CCP. Interventions: Patients received whole-body threshold erythemogenic dose of either 3-times weekly TL-01 or twice-weekly oral 8-MOP PUVA, based on minimal erythema or phototoxic doses. Patients were treated until completely clear. Outcome Measures: Number of treatments to clear, number of days in treatment, number of days in remission, and adverse effects of both therapies were assessed. Results: Forty-five patients completed the study. Those in the PUVA group required significantly fewer treatments to clear (P = .03). There was no significant difference in the number of days to clear or number of days in remission. A similar percentage of patients in the TL-01 and PUVA groups developed minimal perceptible erythema, showing that the regimens were equally erythemogenic. Asymptomatic, well-defined erythema occurred only in the PUVA group. Pruritus and polymorphic light eruption occurred equally in both groups, but only patients in the PUVA group developed nausea. Conclusion: Narrowband UV-B phototherapy, used 3 times weekly, is as effective for the treatment of CPP as oral 8-MOP PUVA used twice weekly.
UR - http://www.scopus.com/inward/record.url?scp=0037342633&partnerID=8YFLogxK
U2 - 10.1001/archderm.139.3.325
DO - 10.1001/archderm.139.3.325
M3 - Article
C2 - 12622624
AN - SCOPUS:0037342633
SN - 0003-987X
VL - 139
SP - 325
EP - 328
JO - Archives of Dermatology
JF - Archives of Dermatology
IS - 3
ER -